8-K: FOXO Technologies Secures $1.5 Million Equity Funding, Reports Significant Financial Turnaround

FOXO Technologies Inc. announced a new Securities Purchase Agreement for $1.5 million in net proceeds from Series A Preferred Stock, highlighting a substantial improvement in stockholders' equity and ongoing efforts to increase revenue.

Summary

• FOXO Technologies Inc. entered into a Securities Purchase Agreement on June 3, 2025, with an existing institutional investor for the issuance of up to 1,650 shares of Series A Cumulative Convertible Redeemable Preferred Stock.
• The agreement is structured in three separate closings of 550 shares each, with the first closing occurring on June 4, 2025.
• If all shares are issued, the Company will receive gross proceeds of $1,650,000, with net proceeds of $1,500,000 after accounting for $150,000 in agreed costs.
• The shares of Series A Preferred Stock are being issued in reliance on the exemption from registration under Section 4(a)(2) of the Securities Act of 1933 and Rule 506 of Regulation D.
• The Company reported net revenues in excess of $3 million and an approximate $4.4 million improvement in stockholders' equity for the first quarter of 2025.
• Stockholders' equity stood at $9.7 million as of March 31, 2025, a significant improvement from the negative $17.5 million reported at September 30, 2024.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the successful equity funding, significant turnaround in stockholders' equity from negative to positive, and reported revenue generation. Management's forward-looking statements about acquisitions and continued growth also contribute to a strong positive outlook, despite acknowledging a history of losses.

Positives

• Successful securing of $1.5 million in net equity funding from an existing institutional investor, providing capital for operations and strategic initiatives.
• Reported net revenues exceeding $3 million for the first quarter of 2025, indicating revenue generation progress.
• Significant improvement in stockholders' equity by approximately $4.4 million in Q1 2025, moving from a negative $17.5 million at September 30, 2024, to a positive $9.7 million at March 31, 2025.
• Management's stated intention to close a recently announced acquisition target in the coming weeks, signaling growth potential.
• The company's ongoing transformation efforts aimed at becoming a successful revenue-generating entity.

Negatives

• The Company incurred $150,000 in agreed costs associated with the $1.65 million gross capital raise, reducing net proceeds.
• The Company has a history of losses and explicitly states that it 'may not achieve or maintain profitability in the future,' indicating ongoing financial challenges despite recent improvements.

Risks

• Changes in the competitive and highly regulated industries in which FOXO operates.
• Variations in operating performance across competitors or changes in laws and regulations affecting FOXO's business.
• The ability to implement FOXO's business plans, forecasts, and other expectations.
• The ability to obtain future financing.
• The risk that FOXO has a history of losses and may not achieve or maintain profitability in the future.
• Potential inability of FOXO to establish or maintain relationships required to advance its goals or to achieve its commercialization and development plans.
• The enforceability of FOXO's intellectual property, including its patents, and the potential infringement on the intellectual property rights of others.
• The risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXO operates.

Future Outlook

FOXO Technologies aims to close one of its recently announced acquisition targets in the coming weeks, continue efforts to increase revenues, and improve its balance sheet. The company is focused on transforming into a successful revenue-generating entity and believes its recent financial improvements will create opportunity and value for shareholders.

Management Comments

• Seamus Lagan, CEO of FOXO, stated, "We are pleased to secure this equity investment into FOXO at this time."
• Mr. Lagan expressed hope "to close one of our recently announced acquisition targets in the coming weeks and continue our efforts to increase our revenues and improve our balance sheet."
• He added, "We are delighted with our continued progress and efforts to transform FOXO into a successful revenue-generating Company."
• Mr. Lagan highlighted the significant transformation, noting, "To report having $9.7M of stockholders equity at March 31, 2025, compared to the negative $17.5M reported for at September 30, 2024 demonstrates a significant transformation in six months that we believe will create opportunity and value for our shareholders."

Industry Context

FOXO Technologies operates across diverse sectors including healthcare, through its ownership of a critical access hospital (Big South Fork Medical) and a behavioral health facility (Myrtle Recovery Centers), and biotechnology, via FOXO Labs, Inc. This equity funding supports the company's ongoing strategic transformation and potential expansion within these highly regulated and competitive industries, particularly as it seeks to close an acquisition target.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or industry benchmarks to assess FOXO's financial results or operational performance against industry standards.

Stakeholder Impact

• Shareholders: The capital raise and significant improvement in stockholders' equity could positively impact shareholder value, although the issuance of preferred stock may lead to future dilution upon conversion.
• Investors: The existing institutional investor is increasing its stake, signaling confidence, while new investors may view the financial turnaround as an attractive opportunity.
• Employees: Improved financial health and potential acquisitions could lead to greater job security and growth opportunities.
• Customers: Continued operations and potential expansion of healthcare facilities (hospital, behavioral health) and biotechnology initiatives could benefit patients and clients.

Next Steps

• Completion of the second closing of the Series A Preferred Stock issuance within two business days of the effective date of a Registration Statement.
• Completion of the third closing of the Series A Preferred Stock issuance within 10 days of the effective date of the Registration Statement.
• Closing of one of the recently announced acquisition targets in the coming weeks.
• Continued efforts to increase revenues and improve the balance sheet.

Key Dates

Recommendation

Keywords

FOXO Technologies, equity funding, preferred stock, capital raise, financial turnaround, healthcare, biotechnology, SEC filing, 8-K, stockholders equity, revenue, acquisition